Q1 EPS Estimates for AstraZeneca Boosted by Zacks Research

AstraZeneca PLC (NASDAQ:AZN) – Zacks Research raised their Q1 2025 earnings estimates for shares of AstraZeneca in a research report issued to clients and investors on Monday, December 30th. Zacks Research analyst R. Department now forecasts that the company will earn $1.07 per share for the quarter, up from their prior estimate of $1.06. The consensus estimate for AstraZeneca’s current full-year earnings is $4.11 per share.

A number of other research analysts have also recently issued reports on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Finally, Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, AstraZeneca has a consensus rating of “Moderate Buy” and a consensus target price of $89.75.

AstraZeneca Stock Down 0.1 %

AZN stock opened at $65.52 on Wednesday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. AstraZeneca has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The stock’s 50 day simple moving average is $67.38 and its 200 day simple moving average is $75.57. The company has a market cap of $203.15 billion, a P/E ratio of 31.35, a price-to-earnings-growth ratio of 1.19 and a beta of 0.45.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping the consensus estimate of $1.01 by $0.03. The company had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company’s quarterly revenue was up 18.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.87 EPS.

Institutional Trading of AstraZeneca

Hedge funds and other institutional investors have recently modified their holdings of the business. Martin Investment Management LLC boosted its stake in AstraZeneca by 2.8% in the 3rd quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock worth $22,571,000 after purchasing an additional 7,615 shares during the period. Integrated Advisors Network LLC boosted its position in shares of AstraZeneca by 46.6% in the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock valued at $3,398,000 after acquiring an additional 13,860 shares during the period. Creative Planning grew its stake in AstraZeneca by 8.0% during the third quarter. Creative Planning now owns 224,751 shares of the company’s stock valued at $17,510,000 after acquiring an additional 16,692 shares in the last quarter. Soros Fund Management LLC grew its stake in AstraZeneca by 8.2% during the third quarter. Soros Fund Management LLC now owns 2,652,771 shares of the company’s stock valued at $206,677,000 after acquiring an additional 201,233 shares in the last quarter. Finally, Optas LLC increased its holdings in AstraZeneca by 173.5% during the 3rd quarter. Optas LLC now owns 15,570 shares of the company’s stock worth $1,213,000 after acquiring an additional 9,877 shares during the period. Institutional investors own 20.35% of the company’s stock.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.